Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02110563
Title Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dicerna Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Stanford Cancer Institute Stanford California 94305 United States Details
University of Chicago Chicago Illinois 60637 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
South Texas Accelerated Research Therapeutics (START)-Midwest Grand Rapids Michigan 49503 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
South Texas Accelerated Research Therapeutics (START), LLC San Antonio Texas 78229 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field